Enzymes in the synthesis of chiral drugs.
The majority of synthetic chiral drugs are now marketed as racemates. This situation is rapidly changing due to the recent advances in asymmetric chemical synthesis and biocatalytic methods. This article reviews the use of enzymes in the synthesis and modification of optically pure drugs. Special attention is focused on the synthesis of new pharmaceuticals which may require efficient procedures for large-scale synthesis in the future.
Margolin
A L
AL
Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215-6300.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism; D001711:Biotransformation; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends; D004798:Enzymes; D004950:Esterases / Q000378:metabolism; D005634:Fructose-Bisphosphate Aldolase / Q000378:metabolism; D008049:Lipase / Q000378:metabolism; D010088:Oxidoreductases / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis*; D011433:Propranolol / Q000378:metabolism; D012702:Serotonin Antagonists / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000378:metabolism; D013237:Stereoisomerism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004798:Enzymes; D004950:Esterases; D005634:Fructose-Bisphosphate Aldolase; D008049:Lipase; D010088:Oxidoreductases; D004364:Pharmaceutical Preparations; D011433:Propranolol; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors